Tickers

1. Composite Trajectory Verdict

The income statement and cash flow statement matter most for assessing GDRX because its digital platform model relies on converting revenue growth into profitable cash generation while managing working capital swings from its pharma direct reimbursement model.

Composite Trajectory: Mixed

Annual 2025 results show improving GAAP profitability (net income up 85% to $30.4M, margin 3.8% vs 2.1%) and operating income up 33% (10-K 2025-12-31, Consolidated Statements of Operations). However, quarterly 2026 results show deteriorating earnings: Q2 2026 net income fell 33% to $8.5M (margin 4.3% vs 6.3%) and Q1 2026 net income fell 89% to $1.2M (margin 0.6% vs 5.4%) year-over-year (10-Q 2026-06-30, Condensed Statements of Operations; 10-Q 2026-03-31, Condensed Statements of Operations). Cash flow trends are similarly split: annual operating cash flow declined 9% to $167.9M (10-K 2025-12-31, Consolidated Statements of Cash Flows), but quarterly operating cash flow improved 57% YTD to $92.7M and 26% in Q1 (10-Q 2026-06-30, Condensed Statements of Cash Flows; 10-Q 2026-03-31, Condensed Statements of Cash Flows). The balance sheet shows annual leverage rising (liabilities up 19%, equity down 15%) but quarterly equity recovering (+5%) and cash increasing (+13%), albeit with a 10-fold gross-up in prescription reimbursement assets and liabilities (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets).

2. Red Flags

• GAAP-to-adjusted earnings gap: Annual 2025 net income margin 3.8% vs Adjusted EBITDA margin 33.9% (non-GAAP); Q2 2026 net income margin 4.3% vs Adjusted EBITDA margin 31.8% (non-GAAP) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Earnings-cash flow divergence: Annual net income rose 85% while operating cash flow fell 9% (10-K 2025-12-31, Consolidated Statements of Operations and Cash Flows). Quarterly Q2 2026 net income fell 33% while YTD operating cash flow rose 57% (10-Q 2026-06-30, Condensed Statements of Operations and Cash Flows).
• Recurring restructuring and legal charges: Restructuring expenses recorded in 2024 ($8.9M), 2025 ($7.7M), Q1 2026 ($5.3M), Q2 2026 ($0.6M); legal settlement expenses in 2024 ($13.0M), 2025 ($5.9M), Q2 2025 ($0.4M); loss on operating lease asset in 2025 ($4.4M) and Q2 2025 ($4.4M) (10-K 2025-12-31, MD&A; 10-Q 2026-03-31, MD&A; 10-Q 2026-06-30, MD&A).
• Monthly Active Consumers declining steadily: 6.7M (Q1 2024) to 5.0M (Q2 2026) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Prescription reimbursement gross-up: Assets grew from $98M to $1,076M and liabilities from $130M to $1,040M in six months, with majority concentrated in two counterparties (10-Q 2026-06-30, Condensed Consolidated Balance Sheets and Note 2).
• Elevated effective tax rates: 46-48% annually, 79.3% in Q1 2026, driven by non-deductible stock compensation (10-K 2025-12-31, MD&A; 10-Q 2026-03-31, MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: While full-year 2025 GAAP net income improved 85% to $30.4M (margin 3.8%) from $16.4M (2.1%) on flat revenue (10-K 2025-12-31, Consolidated Statements of Operations), the two most recent comparable quarters show sharp deterioration. Q2 2026 net income fell 33% to $8.5M (margin 4.3% vs 6.3%) and Q1 2026 net income fell 89% to $1.2M (margin 0.6% vs 5.4%) year-over-year (10-Q 2026-06-30, Condensed Statements of Operations; 10-Q 2026-03-31, Condensed Statements of Operations). Operating income declined 12% in Q2 and 40% in Q1. Prescription transactions revenue dropped 26% in Q2 and 24% in Q1, partially offset by Pharma Direct growth of 76% and 82% and subscription growth of 39% and 16%. Cost of revenue surged 57% in Q2 and 51% in Q1, compressing margins despite lower sales and marketing spend.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Overall Assessment: Annual operating cash flow declined 9% to $167.9M in 2025 from $183.9M in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). However, quarterly trends reversed: YTD Q2 2026 operating cash flow increased 57% to $92.7M from $59.0M, and Q1 2026 operating cash flow increased 26% to $11.8M from $9.4M (10-Q 2026-06-30, Condensed Statements of Cash Flows; 10-Q 2026-03-31, Condensed Statements of Cash Flows). The improvement was driven by favorable working capital timing, particularly collections of prescription reimbursement assets and accounts receivable. Investing cash outflows decreased 49% YTD and 58% in Q1 due to fewer acquisitions. Financing cash outflows fell 86% YTD and 84% in Q1 as share repurchases slowed. Ending cash rose to $296.1M at June 30, 2026 from $261.8M at December 31, 2025 (10-Q 2026-06-30, Condensed Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Annual comparison shows total liabilities rising 19% to $787.8M while equity fell 15% to $616.3M, driven by share repurchases ($216.4M in 2025) and accumulated deficit reduction (10-K 2025-12-31, Consolidated Balance Sheets and Cash Flows). Debt remained stable near $483M. Quarterly, equity recovered 5% to $647.6M and cash increased 13% to $296.1M, but the balance sheet expanded 67% to $2.34B due to a tenfold increase in prescription reimbursement assets ($1.08B vs $98M) and liabilities ($1.04B vs $130M) from the consumer direct pricing program (10-Q 2026-06-30, Condensed Consolidated Balance Sheets and Note 2). These gross balances are concentrated with two counterparties, introducing counterparty risk. The revolving credit facility remains undrawn with $80.4M available (10-Q 2026-06-30, MD&A).

6. Data Gaps

• Full quarterly income statements and cash flows for 2024 (only Q1 and Q2 2025 provided in 10-Qs; Q3/Q4 2024 not available).
• Quarterly balance sheets for 2024 (only year-end 2024 and 2025, plus Q1/Q2 2026).
• Segment-level profitability (company reports single segment).
• Detailed pharma direct revenue breakdown by manufacturer program.
• Quantified impact of TrumpRx platform on revenue and margins.
• Debt maturity schedule beyond 2029 term loan and revolving facility.
• Subscription revenue decomposition by offering (Gold, condition-specific, RxSmartSaver+, Companion).